Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Investor Relations Home

To access The New England Journal of Medicine publication on the Phase 3 ANNEXA studies of andexanet alfa visit: http://www.nejm.org/doi/full/10.1056/NEJMoa1510991

Webcast ImageWebcast
Portola Pharmaceuticals, Inc. Investor Event to Discuss Phase 3 APEX Data  (Live)
05/27/16 at 11:00 a.m. ET
Portola Pharmaceuticals, Inc. Investor Event to Discuss Phase 3 APEX Data
Friday, May 27, 2016 11:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Upcoming EventsMore >>
DateTitle
05/27/16 11:00 a.m. ET
Portola Pharmaceuticals, Inc. Investor Event to Discuss Phase 3 APEX Data
Archived Events
Q1 2016 Portola Pharmaceuticals, Inc. Financial Results Conference Call
Thursday, May 5, 2016 1:30 p.m. PT
DescriptionThis event is audio only.

Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$26.41
Change (%) Stock is Down 0.55 (2.04%)
Volume316,796
Data as of 05/25/16 2:24 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. We are advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhib... More >>

Recent NewsMore >>
DateTitle 
05/23/16Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa™ (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardization Committee Meeting
Webcast of Investor Event to Discuss Phase 3 APEX Data to be Held on Friday, May 27 SOUTH SAN FRANCISCO, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today announced that the full data set from the Phase 3 APEX Study of betrixaban will be featured in an oral session at the 62nd Annual Scientific and Standardization Committee (SSC) Meeting of the International Society on Thrombosis and Haemostasis (ISTH), which will take place from May 25-28 in Montpelli... 
Printer Friendly Version
05/05/16Portola Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA), today provided a corporate update and reported its financial results for the first quarter ended March 31, 2016. “During the first quarter of 2016, we continued to advance the development of our three product candidates. We reported acceptance of our ANDEXXA™ (andexanet alfa) BLA and Phase 3 topline data from the APEX trial of betrixaban, complete... 
Printer Friendly Version
04/28/16Portola Pharmaceuticals to Announce First Quarter 2016 Financial Results and Host Conference Call on Thursday, May 5
SOUTH SAN FRANCISCO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2016, and provide a general business overview on Thursday, May 5, 2016, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Details To access the live conference call, please dial (844) 452-6828 from the U.S. and Canada or +1 (765) 5... 
Printer Friendly Version
04/14/16Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
SOUTH SAN FRANCISCO, Calif., April 14, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that new data from a pharmacokinetic modeling study designed to identify the dose of cerdulatinib for expansion cohorts in a Phase 2 study will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2016, which is taking place from April 16-20 in New Orleans. Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development t... 
Printer Friendly Version
04/06/16Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemostasis (ISTH) SSC Meeting 2016 on May 27, 2016
SOUTH SAN FRANCISCO, Calif., April 06, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that data from its Phase 3 APEX Study of betrixaban will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 62nd Annual SSC (Scientific and Standardization Committee) Meeting, which is taking place from May 25-28 in Montpellier, France. Portola is developing betrixaban, an oral Factor Xa inhibitor anticoagulant, for the prevention of venous thromboem... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.